title: [Introduction of oxaliplatin for treating unresectable advanced or recurrent gastric cancer in clinical practice].
abstract: On the basis of public knowledge-based application, oxaliplatin has recently been approved for treating unresectable advanced or recurrent gastric cancer. With the introduction of oxaliplatin in clinical practice, SOX or CapeOX will be widely used for treating advanced gastric cancer. The safety data of SOX(oxaliplatin 100mg/m2)in Japanese patients with advanced gastric cancer has been reported in a domestic phase III clinical trial. Nevertheless, when using SOX(oxaliplatin 130 mg/m2), it is important to refer to the dose modification criteria given in the SOFT trial. This manuscript summarizes some clinical trials as references and the points to consider while using oxaliplatin for treating gastric cancer in clinical practice.
authors.affiliation: Dept. of Medical Oncology, Hirosaki University Graduate School of Medicine.
authors.forename: Atsushi
authors.initials: A
authors.lastname: Sato
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D009367:Neoplasm Staging; D009944:Organoplatinum Compounds / Q000627:therapeutic use*; D000077150:Oxaliplatin; D012008:Recurrence; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology
chemical_list: D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin